Studies on topical antiinflammatory corticosteroids. III Synthesis and vasoconstrictive activity of 11.BETA.,17.ALPHA.,21-trihydroxy-2'-phenyl-2'H-2,4-pregnadieno(3,2-c)pyrazol-20-one derivatives.
作者:SABURO SUGAI、YOSHIO KAJIWARA、TOSHIFUMI KANBARA、YASUO NAITO、SEIICHIRO YOSHIDA、SANYA AKABOSHI、SHIRO IKEGAMI、YOSHIAKI KAMANO
DOI:10.1248/cpb.34.1613
日期:——
17α-Acyloxy-11β, 21-dihydroxy-2'-phenyl-2'H-2, 4-pregandieno[3, 2-c]pyrazol-20-one derivatives (3a, 3b, 4, 5a and 5c) were synthesized and tested for vasoconstrictive activities. Compound 3b showed the most potent activity, which was greater than that of 9α-fluoro-11β, 21-dihydroxy-16β-methyl-17α-valeroyloxy-1, 4-pregnadiene-3, 20-dione (betamethasone 17-valerate, BV). The activities of all other compounds (3a, 4, 5b and 5c) were rather weaker than that of the mother compound, 11β, 17α, 21-trihydroxy-2'-phenyl-2'H-2, .4-pregnadieno[3, 2-c]pyrazol-20-one (1). In contrast to the case of corticosteroids having a hydrocortisone-type skeleton, esterification of both the 17- and 21-hydroxy groups of the pyrazole-fused compound (1) or the substitution of the 21-hydroxy group of the 17-ester compound (3) with a chlorine atom are not always necessary for the exhibition of higher activity.
合成了 17α-Acyloxy-11β, 21-dihydroxy-2'-phenyl-2'H-2, 4-pregandieno[3, 2-c]pyrazol-20-one 衍生物(3a, 3b, 4, 5a 和 5c),并进行了血管收缩活性测试。化合物 3b 的活性最强,高于 9α-氟-11β,21-二羟基-16β-甲基-17α-戊酰氧基-1,4-孕二烯-3,20-二酮(倍他米松 17-戊酸酯,BV)。所有其他化合物(3a、4、5b 和 5c)的活性都比母体化合物 11β、17α、21-三羟基-2'-苯基-2'H-2,.4-孕二烯并[3,2-c]吡唑-20-酮(1)的活性弱。与具有氢化可的松类骨架的皮质类固醇不同的是,吡唑融合化合物(1)的 17-羟基和 21-羟基的酯化或 17-酯化合物(3)的 21-羟基被氯原子取代并不总是显示较高活性的必要条件。